Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun 22:5:1137637.
doi: 10.3389/ftox.2023.1137637. eCollection 2023.

Ocular surface complications following biological therapy for cancer

Kevin Sheng-Kai Ma  1   2   3 , Ping-Feng Tsai  4 , Tina Yi-Jin Hsieh  5   6 , James Chodosh  7
Affiliations
Review

Ocular surface complications following biological therapy for cancer

Kevin Sheng-Kai Ma et al. Front Toxicol. .

Abstract

Novel and highly effective biological agents developed to treat cancer over the past two decades have also been linked to multiple adverse outcomes, including unanticipated consequences for the cornea. This review provides an overview of adverse corneal complications of biological agents currently in use for the treatment of cancer. Epidermal growth factor receptor inhibitors and immune checkpoint inhibitors are the two classes of biological agents most frequently associated with corneal adverse events. Dry eye, Stevens-Johnson syndrome, and corneal transplant rejection have all been reported following the use of immune checkpoint inhibitors. The management of these adverse events requires close collaboration between ophthalmologists, dermatologists, and oncologists. This review focuses in depth on the epidemiology, pathophysiology, and management of ocular surface complications of biological therapies against cancer.

Keywords: biological therapy; cancer; cornea; immunotherapy; ocular surface; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Chiang C. H., Chiang C. H., Ma K. S., Hsia Y. P., Lee Y. W., Wu H. R., et al. (2022a). The incidence and risk of cardiovascular events associated with immune checkpoint inhibitors in Asian populations. Jpn. J. Clin. Oncol. 52 (12), 1389–1398. 10.1093/jjco/hyac150 - DOI - PMC - PubMed
    1. Chiang C. H., Chiang C. H., Peng C. Y., Hsia Y. P., See X. Y., Horng C. S., et al. (2022b). Efficacy of cationic amphiphilic antihistamines on outcomes of patients treated with immune checkpoint inhibitors. Eur. J. Cancer 174, 1–9. 10.1016/j.ejca.2022.07.006 - DOI - PubMed
    1. Fang T., Maberley D. A., Etminan M. (2019). Ocular adverse events with immune checkpoint inhibitors. J. Curr. Ophthalmol. 31 (3), 319–322. 10.1016/j.joco.2019.05.002 - DOI - PMC - PubMed
    1. Fraunfelder F. T., Fraunfelder F. W. (2012). Trichomegaly and other external eye side effects associated with epidermal growth factor. Cutan. Ocul. Toxicol. 31 (3), 195–197. 10.3109/15569527.2011.636118 - DOI - PubMed
    1. Goleva E., Lyubchenko T., Kraehenbuehl L., Lacouture M. E., Leung D. Y. M., Kern J. A. (2021). Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy. Ann. Allergy Asthma Immunol. 126 (6), 630–638. 10.1016/j.anai.2021.03.003 - DOI - PMC - PubMed